Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian BioSciences Shares Double Premarket After Acceptance of Pre-IND for HIV Treatment

06/14/2021 | 08:43am EDT

By Chris Wack

Enochian BioSciences Inc. shares doubled to $10.19 in premarket trading Monday after the company said the Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for HIV.

The company said written comments are expected this fall.

Enochian BioSciences said the request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy. The patient subsequently achieved viral control for 255 days with an innovative treatment of Natural Killer and Gamma Delta T-cells collected from another person.

During the entire period, no antiviral drugs were given, the company said. It is believed that the GDT cells, a small subset of immune cells that can be infected with HIV, could be a key factor in controlling the virus.

Enochian BioSciences, which holds the exclusive license for the proprietary technology, said the cellular therapy could be an important approach to achieve a "functional cure" of HIV, potentially allowing persons with the virus to stop antiviral treatment for extended periods of time.

The pre-IND submission requested that the novel strategy be extended to persons with HIV who have achieved suppression of the virus with antiviral treatment.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-14-21 0842ET

All news about ENOCHIAN BIOSCIENCES, INC.
07/23ENOCHIAN BIOSCIENCES : Names The Hon. Dr. Mark Dybul as Chief Executive Officer ..
PU
07/23ENOCHIAN BIOSCIENCES INC : Entry into a Material Definitive Agreement, Regulatio..
AQ
07/20ENOCHIAN BIOSCIENCES : Appoints Mark Dybul as CEO
MT
07/20ENOCHIAN BIOSCIENCES : Names The Hon. Dr. Mark Dybul as Chief Executive Officer
AQ
07/20Enochian BioSciences Names the Hon. Dr. Mark Dybul as Chief Executive Officer
CI
07/12ENOCHIAN BIOSCIENCES : Says FDA Accepted its Pre-Investigational New Drug Reques..
MT
07/12ENOCHIAN BIOSCIENCES : Announces FDA Acceptance of Pre-IND Request For Potential..
PU
07/12ENOCHIAN BIOSCIENCES : Announces FDA Acceptance of Pre-IND Request For Potential..
AQ
07/12Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potentia..
CI
07/12Enochian Pre-IND Request for Potential Cure for Hepatitis B Virus Infection A..
DJ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -11,4 M - -
Net cash 2020 1,11 M - -
P/E ratio 2020 -17,1x
Yield 2020 -
Capitalization 256 M 256 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 10
Free-Float 38,2%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
James E. Sapirstein Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.67.12%282
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308